eligibility_summary
Eligible: 0–21-year-olds after allogeneic transplant (any source/conditioning) with CMV, EBV, or adenovirus infection/reactivation refractory to therapy, life expectancy >30 days, no severe uncontrolled infections, uncontrolled acute/chronic GvHD, or severe renal/hepatic injury unrelated to the virus, informed consent required. Exclude: no suitable donor (seronegative/failed secretion test), severe renal/hepatic impairment, graft failure, or malignancy relapse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Virus-specific T cells (VSTs), a biological adoptive cellular therapy generated from a seropositive family donor. Mechanism: donor leukapheresis, T cells are briefly stimulated with CMV/EBV/adenovirus peptides, then IFN-γ–secreting CD4+ and CD8+ T cells are immunomagnetically captured (CliniMACS CCS) and infused. Post-infusion, VSTs recognize HLA-presented viral epitopes, secrete IFN-γ, and kill infected cells via perforin/granzyme, expanding in vivo to restore antiviral immunity. Targets: viral antigens from CMV, EBV, and adenovirus, effector cells are CD4+ Th1 and CD8+ CTLs. Key pathways: TCR–MHC antigen recognition, IFN-γ signaling, and cell-mediated cytotoxicity. Phase I, single-arm in allo-HSCT recipients aged 0–21.